Immunotherapy

A CHANGER

TrialStudied treatmentControl treatmentpatientsROBResultNCT

advanced renal-cell carcinoma

nivolumab
CheckMate 025, 2015nivolumabeverolimusSuggestingNCT01668784
CheckMate 214 ongoing nivolumab+ ipilimumabsunitinib - NCT02231749

melanoma

ipilimumab
Hodi, 2010ipilimumab 3 mg/kggp100previously treatment progression Risk of bias - NCT00094653
Robert (Ipilimumab), 2011ipilimumab 10mg/kg plus dacarbazinedacarbazinepreviously untreated advanced melanoma - NCT00324155
Ahmad Tarhini ongoing ipilimumabinterferon alfa-2b - NCT01274338
CA184-169 ongoing ipilimumab 3 mg/kgipilimumab 10 mg/kg - NCT01515189
EORTC Melanoma Group ongoing ipilimumabplacebo - NCT00636168
nivolumab
CheckMate 238nivolumabipilimumab - NCT02388906
CheckMate 067 (nivo + ipi), 2015nivolumab + ipilimumabipilimumabSuggestingNCT01844505
CheckMate 066 (Robert), 2015nivolumabdacarbazinepreviously untreated advanced melanoma Low risk of bias - NCT01721772
CheckMate 037 (Weber), 2015nivolumabchemotherapy - NCT01721746
CheckMate 067 (nivo vs ipi), 2015nivolumabipilimumab - NCT01844505
CheckMate 067 (nivo + ipi vs nivo), 2015nivolumab + ipilimumabnivolumab - NCT01844505
pembrolizumab
KEYNOTE-054pembrolizumabplacebo - NCT02362594
KEYNOTE 002 (2mg/kg Q3W)pembrolizumab 2mg/kgchemotherapySuggestingNCT01704287
SWOG S1404pembrolizumabhigh dose interferon -
Hamid, 2013pembrolizumabpembrolizumab Exploratory - NCT01295827
KEYNOTE-001, 2014pembrolizumab 2mg/kgpembrolizumab 10mg/kgadvanced melanoma ipilimumab failure Exploratory NegativeNCT01295827
KEYNOTE-006 (every 2W), 2015pembrolizumabipilimumabSuggestingNCT01866319
KEYNOTE-006 (every 3W), 2015pembrolizumab (every 3W)ipilimumabSuggestingNCT01866319
SWOG S1404 ongoing pembrolizumabhigh dose interferon -